ZYNERBA PHARMACEUTICALS, INC. DelveInsight's, "Fragile X Syndrome Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Fragile X Syndrome pipeline landscape. It covers the Fragile X Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Fragile X Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Fragile X Syndrome Pipeline Report *DelveInsight's Fragile X Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Fragile X Syndrome treatment. *The leading companies working in the Fragile X Syndrome Market include
Request a sample and discover the recent advances in Fragile X Syndrome Treatment Drugs @ Fragile X Syndrome Pipeline Report
In the Fragile X Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Fragile X Syndrome clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Fragile X Syndrome Overview
Fragile X syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP).
Find out more about Fragile X Syndrome Therapeutics Assessment @ Fragile X Syndrome Preclinical and Discovery Stage Products
Fragile X Syndrome Emerging Drugs Profile *Zatolmilast:
Fragile X Syndrome Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Fragile X Syndrome therapies. The Fragile X Syndrome companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include
Learn more about the emerging Fragile X Syndrome Pipeline Therapies @ Fragile X Syndrome Clinical Trials Assessment
Scope of the Fragile X Syndrome Pipeline Report *Coverage- Global *Fragile X Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Fragile X Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *
Dive deep into rich insights for new drugs for Fragile X Syndrome Treatment, Visit @ Fragile X Syndrome Market Drivers and Barriers, and Future Perspective
Table of Content *Introduction *Executive Summary *Fragile X Syndrome: Overview *Pipeline Therapeutics *Therapeutic Assessment *Fragile X Syndrome- DelveInsight's Analytical Perspective *In-depth Commercial Assessment *Fragile X Syndrome Collaboration Deals *Late Stage Products (Phase III) *Zatolmilast:
For further information on the Fragile X Syndrome Pipeline therapeutics, reach out to Fragile X Syndrome Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address:
City:
State: NV
Country:
Website: https://www.delveinsight.com/consulting/ci-tracking
Source: www.abnewswire.com
.
(C) 2023 M2 COMMUNICATIONS, source
